Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure

OBJECTIVES: To analyse adverse events (AEs) of special interest across tofacitinib clinical programmes in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC) and psoriasis (PsO), and to determine whether the incidence rates (IRs; unique patients with events per 100 patient-...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R, Nash, Peter, Sands, Bruce E, Papp, Kim, Stockert, Lori, Jones, Thomas V, Tan, Huaming, Madsen, Ann, Valdez, Hernan, Cohen, Stanley B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162077/
https://www.ncbi.nlm.nih.gov/pubmed/34045358
http://dx.doi.org/10.1136/rmdopen-2021-001595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162077/
https://www.ncbi.nlm.nih.gov/pubmed/34045358
http://dx.doi.org/10.1136/rmdopen-2021-001595

Ejemplares similares